Abiopharma

Appili Therapeutics Announces Proposed Non-Brokered Private Placement

Cardiol Therapeutics’ Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases

MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering

The Joint Corp. Board of Directors Authorizes an Additional $12 Million for Stock Repurchase Program

Celcuity Inc. Schedules Release of Third Quarter 2025 Financial Results and Webcast/Conference Call

Anika Reports Third Quarter 2025 Financial Results

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Charles River Laboratories Provides Update on Strategic Review

MindMed to Participate in Upcoming Investor Conferences

Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress